Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Ankenman, R. Articles by Salvatore, M. F. Search for Related Content PubMed Citation Articles by Ankenman, R. Articles by Salvatore, M. F.

Low Dose Alpha-Methyl-Para-Tyrosine (AMPT) in the Treatment of Dystonia and Dyskinesia

Received August 17, 2005; accepted October 31, 2005. Dr. Ankenman is affiliated with the Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky. Dr. Salvatore is affiliated with Madison County Hospital, London, Ohio. Address correspondence to Dr. Ankenman, 306 Whitney-Hendrickson Building, 800 Rose Street, Lexington, KY 40536; docank{at}newave.net (e-mail).

AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.

Get information about faster international access.

Privacy Policy

Copyright © 2007 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us